This patent covers antibodies that bind to mesenchymal stem cells. The antibodies are deposited as hybridomas under accession numbers KCLRF-BP-000123, KCLRF-BP-000124 or KCLRF-BP-000125 at the Korean Cell Line Research Foundation (Cancer Research Institute, Seoul National University, College of Medicine, 28 Yongondong, Chongno-Gu, Seoul, 110-744, Korea). The antigen appears to be about 130 kDa.
It is important to find markers of mesenchymal stem cells since this may lead to different patentable subsets. For example, Angioblast Systems has a patent based on expression of STRO-1 by mesenchymal stem cells. Osiris has similar mesenchymal stem cells except because of a different marker expression profile they have another series of patents.